This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Aug 4;387(5):477-478.

doi: 10.1056/NEJMc2208130.

Gliflozins in the Management of Cardiovascular Disease

Samuel N Heyman¹, Zaid Abassi²

Affiliations

Affiliations

¹ Hadassah Hebrew University Hospital, Jerusalem, Israel.
² Technion Israel Institute of Technology, Haifa, Israel samuel.heyman@mail.huji.ac.il.

PMID: 35921467
DOI: 10.1056/NEJMc2208130

Comment

Gliflozins in the Management of Cardiovascular Disease

Samuel N Heyman et al. N Engl J Med. 2022.

. 2022 Aug 4;387(5):477-478.

doi: 10.1056/NEJMc2208130.

Authors

Samuel N Heyman¹, Zaid Abassi²

Affiliations

¹ Hadassah Hebrew University Hospital, Jerusalem, Israel.
² Technion Israel Institute of Technology, Haifa, Israel samuel.heyman@mail.huji.ac.il.

PMID: 35921467
DOI: 10.1056/NEJMc2208130

Erratum in

Gliflozins in the Management of Cardiovascular Disease.
[No authors listed] [No authors listed] N Engl J Med. 2022 Sep 29;387(13):1244. doi: 10.1056/NEJMx220008. N Engl J Med. 2022. PMID: 36173028 No abstract available.

No abstract available

PubMed Disclaimer

Comment on

Gliflozins in the Management of Cardiovascular Disease.
Braunwald E. Braunwald E. N Engl J Med. 2022 May 26;386(21):2024-2034. doi: 10.1056/NEJMra2115011. N Engl J Med. 2022. PMID: 35613023 Review. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information